OMEROS CORP 10-Q

ITEM 5. OTHER INFORMATION (a) None . (b) None . (c) Our directors and Section 16 reporting officers may from time to time enter into plans or other arrangements for the purchase or sale of our shares that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”). During the three months ended June 30, 2024, the following 10b5-1 Plans were adopted: ● On June 14, 2024 , Thomas J. Cable , a member of our Board of Directors , adopted a 10b5-1 Plan providing for the potential exercise of vested stock options and the associated sale of up to 27,500 shares of our common stock under certain conditions. Mr. Cable’s 10b5-1 Plan will remain in effect until the earliest of (i) June 12, 2026, (ii) the date on which all of the shares of common stock covered by the 10b5-1 Plan have been sold, and (iii) such time as Mr. Cable’s 10b5-1 Plan is otherwise terminated or expires according to its terms. ● On June 27, 2024 , Gregory A. Demopulos, M.D. , our President, Chief Executive Officer and Chairman of the Board of Directors , adopted a 10b5-1 Plan providing for the potential exercise of vested stock options for 449,999 shares of our common stock, and the associated sale of up to all or a portion of the underlying shares under certain conditions. Dr. Demopulos’ 10b5-1 Plan will remain in effect until the earliest of (i) October 29, 2024 (which is the expiration date of the stock options covered by the 10b5-1 Plan), (ii) the date on which all of the shares of common stock covered by the 10b5-1 Plan have been sold, and (iii) such time as Dr. Demopulos’ 10b5-1 Plan is otherwise terminated or expires according to its terms. No other directors or Section 16 reporting officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5 - 1(c) under the Exchange Act or any “non-Rule 10b5 - 1 trading arrangement” (as defined in Item 408(c) of Regulation S-K) during the three months ended June 30, 2024. 26 Table of Contents ITEM 6. EXHIBITS Exhibit Number ​ Description ​ ​ ​ 10.1 † Credit and Guaranty Agreement, dated as of June 3, 2024, among the Company, certain subsidiaries of the Company, as guarantors, various Lenders and Wilmington Savings Fund Society, FSB, as Administrative Agent and Collateral Agent (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed June 3, 2024) 10.2 Pledge and Security Agreement, dated as of June 3, 2024, between the Company, nura inc. and Wilmington Savings Fund Society, FSB, as Collateral Agent (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K filed June 3, 2024) 10.3 Fifteenth Amendment to Lease dated November 1, 2022 between Omeros Corporation and BMR-201 Elliott Avenue LLC 31.1 ​ Certification of Principal Executive Officer Pursuant to Rule 13-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2 ​ Certification of Principal Financial Officer Pursuant to Rule 13-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1 ​ Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2 ​ Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS ​ Inline XBRL Instance Document 101.SCH ​ Inline XBRL Taxonomy Extension Schema Document 101.CAL ​ Inline XBRL Taxonomy Extension Calculation Link base Document 101.DEF ​ Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB ​ Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE ​ Inline XBRL Taxonomy Extension Presentation Linkbase Document 104.1 ​ Cover Page Interactive Data File, formatted in Inline XBRL (included in Exhibit 101) † Certain identified information has been excluded from the exhibit because it both (A) is not material and (B) would be competitively harmful if publicly disclosed. The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Omeros Corporation under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. ​ 27 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ OMEROS CORPORATION ​ ​ Dated: August 7, 2024 /s/ Gregory A. Demopulos ​ Gregory A. Demopulos, M.D. ​ President, Chief Executive Officer and Chairman of the Board of Directors ​ ​ Dated: August 7, 2024 /s/ David J. Borges ​ David J. Borges ​ Vice President, Finance, Chief Accounting Officer and Treasurer ​ 28